Published in J Pediatr on December 01, 1999
Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother (2004) 0.82
Highly active antiretroviral therapy: progress and pitfalls. J Pediatr (1999) 0.75
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet (1995) 3.43
Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev (1992) 3.30
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22
The checkpoint protein Ddc2, functionally related to S. pombe Rad26, interacts with Mec1 and is regulated by Mec1-dependent phosphorylation in budding yeast. Genes Dev (2000) 2.82
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 2.77
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA (1994) 2.56
Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst (1997) 2.45
In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis (1996) 2.34
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med (2003) 2.30
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood (2000) 1.94
Early T-helper cell defects in HIV infection. AIDS (1991) 1.93
Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol (1996) 1.93
Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS (2000) 1.91
Mother-to-child transmission of hepatitis C virus detected by nested polymerase chain reaction. J Infect Dis (1992) 1.90
HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS (1999) 1.89
Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis (1999) 1.88
Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS (1998) 1.86
Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol (1993) 1.84
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS (1998) 1.81
Successful stent delivery with deep seating of 6 French guiding catheters in difficult coronary anatomy. Catheter Cardiovasc Interv (1999) 1.81
Hawking radiation from ultrashort laser pulse filaments. Phys Rev Lett (2010) 1.80
Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Am J Gastroenterol (2011) 1.79
Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest (1989) 1.77
Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today (1996) 1.75
Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol (2000) 1.69
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis (1995) 1.69
Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS (2000) 1.66
Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer (2003) 1.65
Alloimmunization as an AIDS vaccine? Science (1993) 1.58
A three-year diagnostic and epidemiological study on viral infantile diarrhoea in Rome. Epidemiol Infect (1988) 1.57
SPECT during sleepwalking. Lancet (2000) 1.54
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1997) 1.54
Characterization of mec1 kinase-deficient mutants and of new hypomorphic mec1 alleles impairing subsets of the DNA damage response pathway. Mol Cell Biol (2001) 1.53
The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS (1999) 1.52
Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy. Lancet (1998) 1.50
Behavioral and psychological disorders in uninfected children aged 6 to 11 years born to human immunodeficiency virus-seropositive mothers. J Dev Behav Pediatr (1999) 1.49
Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J Clin Invest (1991) 1.44
Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.43
In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis (1996) 1.41
Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ (1994) 1.41
Antibiotic and cholestyramine treatment of chronic diarrhea in HIV-infected children. Ital J Gastroenterol Hepatol (1997) 1.40
False positives and false negatives: is the answer relatively simple? Acta Psychiatr Scand (2012) 1.39
Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res (1996) 1.39
Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS (1996) 1.39
A strategy for prophylactic vaccination against HIV. Science (1993) 1.38
Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children. AIDS (1991) 1.37
Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost (1997) 1.36
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS (1999) 1.36
Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis (1996) 1.36
CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin Exp Immunol (1996) 1.35
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett (2001) 1.31
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol (2011) 1.30
Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing. Eur Respir J (2000) 1.30
CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol (2000) 1.28
Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 1.28
Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS (1998) 1.28
The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis (2008) 1.27
Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol (1993) 1.25
Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood (1996) 1.23
T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. AIDS (2001) 1.23
Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology (1996) 1.23
Ranitidine pharmacokinetics in newborn infants. Arch Dis Child (1993) 1.21
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost (2009) 1.19
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother (2000) 1.18
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med (2007) 1.17
Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol (2008) 1.16
Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS (2001) 1.16
Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori (1982) 1.16
Diazepam elimination in premature and full term infants, and children. J Perinat Med (1973) 1.15
Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.14
Effect of a rapid influenza diagnosis. Arch Dis Child (2003) 1.14